JB
CBIO

Julian Baker’s Crescent Biopharma CBIO Stock Holding History

Julian Baker’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,912
Closed -$4.7M – 106
2018
Q2 		$4.7M Sell
2,912
-2,721
-48% -$4.68M 0.04% 77
2018
Q1 		$9.14M Hold
5,633
– – 0.08% 62
2017
Q4 		$9.46M Hold
5,633
– – 0.08% 59
2017
Q3 		$7.88M Hold
5,633
– – 0.06% 60
2017
Q2 		$6.29M Buy
5,633
+1,821
+48% +$1.5M 0.06% 60
2017
Q1 		$2.07M Hold
3,812
– – 0.02% 88
2016
Q4 		$2.33M Hold
3,812
– – 0.02% 89
2016
Q3 		$2.73M Hold
3,812
– – 0.02% 84
2016
Q2 		$2.77M Buy
+3,812
New +$2.63M 0.03% 85

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Julian Baker's CBIO Position: Q3 2018 in Review

Julian Baker sold out of Crescent Biopharma (CBIO) in Q3 2018, closing a stake of 2,912 shares — an estimated $4.7M sold.

Julian Baker first reported a position in CBIO in Q2 2016 and held it in 9 quarters. The position peaked at $9.46M in Q4 2017. 85 funds tracked by Wall St. Rank hold CBIO as of Q3 2018.

  • Julian Baker reported no remaining Crescent Biopharma position as of Q3 2018 after selling out during the quarter.
  • Julian Baker sold 2,912 Crescent Biopharma shares in Q3 2018, an estimated $4.7M.
  • Julian Baker first reported a position in Crescent Biopharma in Q2 2016 and held it in 9 quarters.
  • Julian Baker's Crescent Biopharma position peaked at $9.46M in Q4 2017.
  • 85 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.